Saccharomyces Cerevisiae Glucan IgG

If gut symptoms raise the Crohn's-versus-ulcerative-colitis question, the answer changes the workup. Crohn's can involve the small bowel and deeper layers of the gut. Ulcerative colitis is centered in the colon. ASCA IgG helps only after that question is already on the table.

The test is not a screen for everyone with loose stools. Current diagnostic guidelines put endoscopy, biopsies, stool testing, imaging, and inflammation markers first. ASCA is an add-on clue. A positive result can support Crohn's. A negative result can't rule it out.

What This Antibody Measures

This test measures IgG antibodies in serum. IgG is the longer-lived antibody class often used to mark a past or steady immune response. The target used in most ASCA assays is a mannan pattern from the cell wall of Saccharomyces cerevisiae.

Mannan is a chain of sugars on the outside of some fungi. The lab antigen is baker's and brewer's yeast, but the result is not a food diary. Candida and other fungi can carry related sugar patterns, so a positive result means your immune system recognizes this fungal pattern. It doesn't prove that eating yeast caused the result.

Telling Crohn's From Colitis

Across studies, ASCA behaves like a confirmation clue, not a rule-out test. In a 60-study meta-analysis, the ASCA-positive and pANCA-negative pattern caught only about half of Crohn's cases, but specificity was about 93 percent. That is the shape of the test: useful when positive, weak when negative.

That meta-analysis pooled ASCA isotypes, so it is evidence about the family of ASCA tests rather than IgG alone. IgG alone has the same problem. One Italian cohort found ASCA IgG sensitivity of 44 percent and specificity of 98 percent for Crohn's. When IgG and IgA were both positive, specificity reached 100 percent in that cohort. That sounds stronger than it is. The symptoms, scope, imaging, and biopsies still decide what the result means.

A common pattern is ASCA positive with pANCA negative. pANCA leans more toward ulcerative colitis. ASCA-positive and pANCA-negative favors Crohn's, especially when symptoms or imaging point to the small bowel.

What It Can Say About Crohn's Type

In people already diagnosed with Crohn's, ASCA positivity and higher levels often track with small-bowel or upper-gut involvement rather than Crohn's limited to the colon. They also track with more complicated disease behavior: narrowing, penetrating complications, and higher surgery rates in several cohorts.

Many of these studies measured IgA and IgG together, so treat this as ASCA-family evidence. IgG by itself may not carry the full signal in every population.

In children, one prospective cohort found ASCA-positive Crohn's was linked with more extensive endoscopic disease at diagnosis. In the subgroup treated with biologic drugs, ASCA IgG-positive children relapsed much less often than IgG-negative children. That was one cohort, not a treatment rule.

About 14 percent of children changed ASCA IgA or IgG status over time, so pediatric results are less fixed than adult results.

Before Symptoms

ASCA can appear before Crohn's is diagnosed, but the size of that signal depends on the cohort. In one military serum-bank study, ASCA was present in about a third of people who later developed Crohn's, on average 38 months before diagnosis, and in none of the matched controls. A later Swedish cohort found a smaller gap: 9.3 percent before Crohn's versus 2.8 percent in controls.

The stronger pre-diagnosis signal comes from panels, not ASCA IgG alone. In healthy first-degree relatives of people with Crohn's, having two or more antimicrobial antibodies, including ASCA IgA or IgG, was linked with about a six-and-a-half-fold higher chance of later Crohn's. That result held even after accounting for inflammation markers and genetic risk.

Knowing this early has not been shown to prevent Crohn's. There is no proven drug or diet for someone who has only the antibody and no disease. It buys awareness, not a prevention plan.

Beyond the Gut

ASCA is not Crohn's-specific outside the right setting. In one type 1 diabetes study, ASCA IgG was present in 21 percent of patients and 2.5 percent of controls. In people with anti-beta2-glycoprotein antibodies, ASCA IgG was present in 15.6 percent versus 2.5 percent of controls. Active celiac disease and alcohol-related liver disease can raise it too.

Parkinson's disease and gastrointestinal Behcet's disease have early reports too. The Parkinson's data come from one case-control cohort. For gastrointestinal Behcet's, a meta-analysis found ASCA was linked with gut involvement, but it did not cleanly separate Behcet's from intestinal tuberculosis and Crohn's.

So a positive result is not simply good or bad. In someone with small-bowel symptoms it supports Crohn's. In a healthy relative it is a risk clue. In someone with celiac disease or liver disease, it may be collateral immune noise. The setting does most of the interpreting.

Why Retesting Usually Adds Little

Most blood markers move. ASCA usually doesn't move much. Levels stayed stable after intestinal surgery in Crohn's and did not change compared with placebo during a year of mesalamine in the strongest placebo-controlled trial, though a smaller study reported lower IgG titers on the drug. Prednisolone lowered IgG and IgA levels over the first few weeks, but ASCA status usually stayed stable.

That changes how to use it. A single baseline result carries most of the value. Retesting every few months is usually a waste. A repeat can make sense when the first result is borderline, when the lab method changed, or in children whose status can shift as disease activity changes.

How to Read the Result

A positive result with symptoms is a lead toward Crohn's, not a diagnosis. A positive result without symptoms and only family history is weaker. A negative result doesn't clear Crohn's when the symptoms, imaging, or biopsies still point that way.

The decision follows the pattern: symptoms, stool inflammation, blood inflammation, celiac testing, infection testing, imaging, and what the bowel looks like under direct examination. ASCA changes the odds. It doesn't replace the workup.

When a Result Can Mislead You

• Assay mismatch: different labs use different methods and report units differently. Compare repeat results only from the same lab and method.
• Steroids: corticosteroids can lower IgG and IgA levels within a few weeks. A lower number on steroids doesn't mean Crohn's has resolved.
• Positive without Crohn's: celiac disease, chronic liver disease, type 1 diabetes, and some other autoimmune settings can raise ASCA.
• Ancestry and disease location: ASCA is less sensitive in some East Asian cohorts and in Crohn's limited to the colon, so a negative result carries little weight there.
• IgG versus ASCA panels: some studies combine IgG and IgA. Evidence from combined ASCA panels should not be read as if it came from IgG alone.